Stay updated on Mirvetuximab Soravtansine Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Soravtansine Clinical Trial page.

Latest updates to the Mirvetuximab Soravtansine Clinical Trial page
- ChecktodayChange DetectedDifference0.9%
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check22 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the details of a study on mirvetuximab soravtansine (IMGN853) for ovarian cancer, including its purpose, study design, and inclusion/exclusion criteria. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference16%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.9%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.9%
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
Stay in the know with updates to Mirvetuximab Soravtansine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Soravtansine Clinical Trial page.